XML 38 R22.htm IDEA: XBRL DOCUMENT
v3.25.2

Equity Compensation Plans and Other Incentive Compensation | 12 Months Ended
--- | ---
May 31, 2025
Share-Based Payment Arrangement [Abstract] |
Equity Compensation Plans and Other Incentive Compensation | 10. Equity Compensation Plans and Other Incentive Compensation The Company’s long-term incentive plans allow for the grant of various types of share-based awards to officers, directors and other key employees of the Company. Incentive and non-qualified options to purchase shares of common stock have been granted under the terms of the 2018 and 2023 Omnibus Incentive Plans. These options are granted at an exercise price equal to the closing price of the common stock on the date of grant. Options vest ratably over three and five year periods and the contractual terms are generally five, seven or ten years. The fair value of the options was estimated at the date of the grant using the Black-Scholes option pricing model. The Company granted restricted stock units (RSUs) under the terms of the 2018 and 2023 Omnibus Incentive Plans, which vest ratably over three and five year periods. The fair value of the RSUs is determined based on the closing price of the common stock on the date of grant. Remaining shares available for grant under share-based compensation plans were 13,817,754 at May 31, 2025, 16,778,458 at May 31, 2024, and 2,871,000 at May 31, 2023. Compensation expense related to share-based awards was $17,291, $13,768, and 10,177 in fiscal years 2025, 2024 and 2023, respectively. Options
(option amounts in thousands) |  | Options |  |  | Weighted-Average Exercise Price |  |  | Weighted-Average Grant Date Fair Value |
Outstanding at May 31, 2022 (1,191 exercisable) |  |  | 3,244 |  |  | $ | 32.13 |  |  | $ | 7.66 |
Granted |  |  | 1,704 |  |  |  | 14.68 |  |  |  | 4.61 |
Exercised |  |  | (22 | ) |  |  | 14.78 |  |  |  | 4.23 |
Forfeited |  |  | (704 | ) |  |  | 29.81 |  |  |  | 7.26 |
Outstanding at May 31, 2023 (1,401 exercisable) |  |  | 4,222 |  |  |  | 25.56 |  |  |  | 6.51 |
Granted |  |  | 1,949 |  |  |  | 15.43 |  |  |  | 5.98 |
Exercised |  |  | (11 | ) |  |  | 13.61 |  |  |  | 4.44 |
Forfeited |  |  | (1,224 | ) |  |  | 30.27 |  |  |  | 7.26 |
Outstanding at May 31, 2024 (1,518 exercisable) |  |  | 4,936 |  |  |  | 20.41 |  |  |  | 6.12 |
Granted |  |  | 2,002 |  |  |  | 15.47 |  |  |  | 4.96 |
Exercised |  |  | (23 | ) |  |  | 14.50 |  |  |  | 4.59 |
Forfeited |  |  | (988 | ) |  |  | 27.92 |  |  |  | 7.10 |
Outstanding at May 31, 2025 ( 2,142 exercisable) |  |  | 5,927 |  |  | $ | 17.51 |  |  | $ | 5.56 |
The following is a summary of stock options outstanding at May 31, 2025:
|  | Options Outstanding |  |  | Options Exercisable |
|  |  |  |  | Average Contractual |  |  | Weighted-Average |  |  |  |  |  | Weighted-Average |
(option amounts in thousands) |  |  |  |  | Life |  |  | Exercise |  |  |  |  |  | Exercise |
Range of Exercise Price |  | Number |  |  | (in years) |  |  | Price |  |  | Number |  |  | Price |
$5.14 - $20.00 |  |  | 5,129 |  |  |  | 5.5 |  |  | $ | 14.93 |  |  |  | 1,552 |  |  | $ | 14.34 |
$20.01 - $28.00 |  |  | 78 |  |  |  | 3.5 |  |  |  | 23.57 |  |  |  | 78 |  |  |  | 23.57 |
$28.01 - $36.00 |  |  | 452 |  |  |  | 1.2 |  |  |  | 31.87 |  |  |  | 344 |  |  |  | 32.16 |
$36.01 - $42.46 |  |  | 268 |  |  |  | 1.4 |  |  |  | 40.96 |  |  |  | 168 |  |  |  | 41.02 |
|  |  | 5,927 |  |  |  | 4.9 |  |  | $ | 17.51 |  |  |  | 2,142 |  |  | $ | 19.63 |
The weighted average exercise price of shares subject to options that were exercisable at May 31, 2024 and 2023 was $26.11 and $31.54, respectively. Remaining compensation cost to be expensed in future periods for non-vested options was $13,488 at May 31, 2025, with a weighted average expense recognition period of 1.8 years.
|  | Year Ended May 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Aggregate intrinsic value of options outstanding |  | $ | 113 |  |  | $ | 55 |  |  | $ | 6,154 |
Aggregate intrinsic value of options exercisable |  |  | — |  |  | $ | 5 |  |  | $ | 42 |
Aggregate intrinsic value of options exercised |  | $ | 46 |  |  | $ | 37 |  |  | $ | 73 |
The fair value of stock options granted was estimated using the following weighted-average assumptions:
|  | Year Ended May 31, |
|  | 2025 |  |  | 2024 |  |  | 2023 |
Risk-free interest rate |  |  | 3.7 | % |  |  | 4.7 | % |  |  | 3.3 | %
Expected dividend yield |  |  | 0.0 | % |  |  | 0.0 | % |  |  | 0.0 | %
Expected stock volatility |  |  | 38.1 | % |  |  | 37.3 | % |  |  | 34.0 | %
Expected option life |  | 3.4 years |  |  | 4.5 years |  |  | 4.5 years |
The risk-free interest rate for periods within the expected life of options granted is based on the U.S. Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on historical volatility of the Company’s stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data. We include recent historical experience in estimating our forfeitures. As employees terminate, grant tranches expire or as forfeitures are known, estimated expense is adjusted to actual. For options granted in fiscal years 2025, 2024 and 2023, the Company recorded charges in general and administrative expense based on the fair value of stock options using the straight line method over the vesting period of three to five years. Restricted Stock Units The remaining weighted-average period for the Company's outstanding RSUs is 1.8 years. On May 31, 2025, there was $11,187 in unamortized compensation cost related to non-vested RSUs. The fair value of restricted stock units vested during fiscal years 2025, 2024 and 2023 was $5,208, $3,835 and $820, respectively.
(RSU amounts in thousands) |  | RSUs |  |  | Weighted Average Grant Date Fair Value |
Outstanding at May 31, 2023 |  |  | 766 |  |  | $ | 19.30 |
Granted |  |  | 574 |  |  |  | 15.55 |
Released |  |  | (230 | ) |  |  | 18.53 |
Forfeited |  |  | (149 | ) |  |  | 19.98 |
Outstanding at May 31, 2024 |  |  | 961 |  |  |  | 17.17 |
Granted |  |  | 537 |  |  |  | 15.49 |
Released |  |  | (374 | ) |  |  | 16.89 |
Forfeited |  |  | (120 | ) |  |  | 17.47 |
Outstanding at May 31, 2025 |  |  | 1,004 |  |  | $ | 16.25 |
The weighted average grant date fair value of the fiscal year 2023 awards was $13.83. Employee Stock Purchase Plan The Company offers eligible employees the option to purchase common stock at a 5% discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of the 2021 Employee Stock Purchase Plan. The discount is recorded in general and administrative expense. Total individual purchases in any year are limited to 10% of compensation. Shares purchased by employees through this program were 157,648 in fiscal 2025, 134,810 in fiscal 2024, and 94,604 in fiscal 2023. As of May 31, 2025, common stock totaling 588,865 of the 1,000,000 authorized shares remained reserved for issuance under the plan. Defined Contribution Benefit Plan and Bonus Compensation The Company maintains a defined contribution 401(k) benefit plan covering substantially all domestic employees. Employees are permitted to defer compensation up to IRS limits, with Neogen matching 100% of the first 3% of deferred compensation and 50% of the next 2% of deferred compensation. Neogen’s expense under this plan was $3,726, $3,368, and $2,439 in fiscal years 2025, 2024 and 2023, respectively. The Company also offers an annual bonus opportunity to certain employees, as an additional component of their compensation. Amounts are determined based on company performance and employee performance. The bonus amounts earned during fiscal year 2025 will be paid to employees in the first quarter of fiscal 2025. As of May 31, 2025 and 2024, the Company had an accrued bonus of $1,828 and $8,056, respectively, recorded within accrued compensation on the consolidated balance sheets.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration